Welcome to the e-CCO Library Archive!
OP001
A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulas in Crohn’s disease
J. Panés*1, D. García-Olmo2, G. Van Assche3, J. F. Colombel4, W. Reinisch5, D. C. Baumgart6, M. Nachury7, M. Ferrante3, L. Kazemi-Shirazi5, J. C. Grimaud8, F. de la Portilla9, E. Goldin10, A. Leselbaum11, M. C. Diez11, S. Danese12
1Hospital Clinic Barcelona, Barcelona, Spain, 2Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, 3University Hospitals Leuven, KU Leuven, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, New York, New York, United States, 5Medical University of Vienna, Vienna, Austria, 6Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, 7CHU Lille, Lille, France, 8Hôpital Nord, Marseille, France, 9Hospital Virgen del Rocío, Sevilla, Spain, 10Sharee Zedek MC, Jerusalem, Israel, 11TiGenix, Madrid, Spain, 12Istituto Clinico Humanitas, Milano, Italy
OP002
Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitis
R. Atreya*1, A. Öst2, C. Admyre3, A. Karlsson3, T. Knittel3, J. Kowalski3, F. Scaldaferi4, M. Neurath1, C. Hawkey5
1University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, 2Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, 3Index Pharmaceuticals, Stockholm, Sweden, 4Catholic University of Rome, Internal Medicine Department / Gastroenterology Division, Rome, Italy, 5Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom
OP003
Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibody’s or clinical/biochemical markers play a more important role?
P. A. Golovics*1, Z. Vegh1, M. Rutka2, K. Gecse1, A. Balint2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, G.T. Toth13, A. Vincze14, E. Biro15, B. Lovasz1, Z. Kurti1, F. Nagy12, T. Molnar2, P. Lakatos1
1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2University of Szeged, First Department of Medicine, Szeged, Hungary, 3Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, 4Peterfy Hospital, First Department of Medicine, Budapest, Hungary, 5Zala County Hospital, Second Department of Medicine, Zalaegerszeg, Hungary, 6B-A-Z County and University Teaching Hospital, Second Department of Medicine, Miskolc, Hungary, 7Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, 8Semmelweis University, Second Department of Medicine, Budapest, Hungary, 9University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, 10Markusovszky Hospital, First Department of Medicine and Gastroenterology, Szombathely, Iceland, 11Tolna County Teaching Hospital, First Department of Gastroenterology, Szekszard, Hungary, 12University of Szeged, First Department of Internal Medicine, Szeged, Hungary, 13Janos Hospital, Department of Gastroenterology, Budapest, Hungary, 14University of Pécs, First Department of Medicine, Pécs, Hungary, 15Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary
OP004
Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn’s disease
A. Stojmirovic*, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman
Janssen R & D, LLC, Spring House, Pennsylvania, United States
OP005
A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease
T. Billiet*1, I. Cleynen1, M. Ferrante2, G. Van Assche2, A. Gils3, S. Vermeire2
1Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Gastroenterology - Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium
OP006
Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapy
M. Wildenberg*1, P. Koelink2, K. Diederen2, A. te Velde2, V. Nuij3, M. Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude3, G. D’Haens1, G. van den Brink1
1Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands, 2Academic Medical Centre, Tytgat Institute, Amsterdam, Netherlands, 3Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, 4Beatson Institute for Cancer Research, Glasgow, United Kingdom
OP007
Comprehensive epigenome-wide DNA methylation profiling in inflammatory bowel disease
N. Ventham*1, N. Kennedy1, A. Adams1, R. Kalla1, S. Heath2, K. O’Leary1, H. Drummond1, D. Wilson3, T. IBD-BIOM Consortium1, T. IBD-CHARACTER Consortium1, I. Gut2, E. R. Nimmo1, J. Satsangi1
1University of Edinburgh, CGEM, Edinburgh, United Kingdom, 2Centro Nacional de Análisis Genómico, Barcelona, Spain, 3University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom
OP008
Genotype-phenotype analysis across 130 422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis
R. Alberts*1, E. M. de Vries2, G. Alexander3, D. Alvaro4, A. Bergquist5, U. Beuers2, E. Björnsson6, K. M. Boberg7, C. L. Bowlus8, R. W. Chapman9, O. Chazouillères10, A. Cheung11, G. Dalekos12, B. Eksteen13, D. Ellinghaus14, M. Färkkilä15, E. A. Festen1, A. Floreani16, T. Folseraas7, E. Goode17, D. N. Gotthardt18, G. M. Hirschfield19, B. van Hoek20, K. Holm7, S. Hohenester21, J. R. Hov7, F. Imhann1, P. Invernizzi22, X. Jiang7, J. Eaton23, B. D. Juran24, K. N. Lazaridis24, V. Leppa25, J. Z. Liu26, J. Löfberg27, M. P. Manns28, H.-U. Marschall29, M. Marzioni30, A. L. Mason31, E. Melum7, P. Milkiewicz32, T. Müller33, A. Pares34, C. Rupp35, S. M. Rushbrook36, C. Rust37, F. Sampaziotis38, R. N. Sandford39, C. Schramm40, S. Schreiber14, E. Schrumpf7, M. Silverberg41, B. Srivastava39, M. Sterneck42, A. Teufel43, L. Tittmann44, L. Vallier38, A. V. Vila1, B. de Vries1, T. J. Weismüller28, C. Wijmenga45, K. Zachou46, A. Franke14, C. A. Anderson47, T. H. Karlsen7, C. Y. Ponsioen2, R. K. Weersma1
1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2Academic Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 3University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, 4Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, 5Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, 6Landspitali University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, 7Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Centre, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, 8University of California Davis, Division of Gastroenterology and Hepatology, Davis, California, United States, 9John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, 10Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, 11University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, 12Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, 13University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, 14Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, 15Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, 16University of Padova, Dept. of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, 17Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, 18University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, 19University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, 20Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 21University of Munich, Department of Medicine II, Munich, Germany, 22Humanitas Clinical and Research Centre, Centre for Autoimmune Liver Diseases, Rozzano, Italy, 23Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 24Mayo Clinic, College of Medicine, Centre for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 25Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, 26Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, 27Karolinska Institute, Department of, Stockholm, Sweden, 28Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, 29Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, 30Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, 31University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Alberta, Canada, 32Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, 33Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, 34University of Barcelona, Liver Unit, Hospital Clinic, I.D.I.B.A.P.S., C.I.B.E.R.ehd, Barcelona, Spain, 35University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, 36University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, 37University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, 38Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, 39University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, 40University Medical Centre Hamburg-Eppendorf, 1st Department of Medicine, Hamburg, Germany, 41Mount Sinai Hospital Toronto, Inflammatory Bowel Disease Group, Zane Cohen Centre for Digestive Diseases, Toronto, Ontario, Canada, 42University Medical Centre Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, 43University of Mainz, First Department of Medicine, Mainz, Germany, 44Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, 45University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 46University of Thessaly, Department of Internal Medicine, Larissa, Greece, 47Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, Massachusetts, United States
OP009
Gene-microbiome interactions underlying the onset and the clinical phenotypes of inflammatory bowel disease
F. Imhann*1, A. Vich Vila1, M. J. Bonder2, D. Gevers3, J. Fu2, M. C. Visschedijk1, L.M. Spekhorst1, L. Franke2, H. van Dullemen1, R. W. F. Ter Steege1, C. Huttenhower4, G. Dijkstra1, R. J. Xavier3, C. Wijmenga2, E. A. M. Festen1, A. Zhernakova2, R. K. Weersma1
1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, 4Harvard School of Public Health, Biostatistics Department, Boston, Massachusetts, United States
OP010
Azathioprine dose reduction in patients with inflammatory bowel disease on combination therapy: a prospective study
E. Del Tedesco1, S. Paul2, H. Marotte3, C. Jarlot1, N. Williet4, J. M. Phelip4, L. Peyrin Biroulet5, J. F. Colombel6, X. Roblin*4
1University Hospital, Gastroenterology, Saint-Etienne, France, 2University of Saint-Etienne, Immunology, Saint-Etienne, France, 3University Hospital, Rheumatology, Saint-Etienne, France, 4CHU Saint-Etienne, Saint-Etienne, France, 5CHU de Nancy, Department of Gastroenterology, Vandoeuvre-lès-nancy, France, 6Mount Sinai Hospital, New York, New York, United States
OP011
Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study)
T. Matsumoto*1, S. Motoya2, K. Watanabe3, T. Hisamatsu4, H. Nakase5, N. Yoshimura6, T. Ishida7, S. Kato8, T. Nakagawa9, M. Esaki10, M. Nagahori11, T. Matsui12, Y. Naito13, T. Kanai14, Y. Suzuki15, M. Nojima16, M. Watanabe11, T. Hibi17
1Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, 2Sapporo Kosei General Hospital, Inflammatory Bowel Disease Centre, Sapporo, Japan, 3Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, 4Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 5Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan, 6Tokyo Yamate Medical Centre, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, 7Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 8Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, 9Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan, 10Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 11Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, 14Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 15Toho University Sakura Medical Centre, Department of Internal Medicine, Sakura, Japan, 16The Institute of Medical Science Hospital, The University of Tokyo, Centre for Translational Research, Tokyo, Japan, 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan
OP012
Risk factors for colorectal neoplasia in ulcerative colitis: results from the largest and longest-running colonoscopic surveillance programme
C. H. R. Choi*1, 2, I. Al Bakir1, 2, N. S. J. Ding1, M. Moorghen1, S. Thomas-Gibson1, J. Warusavitarne1, B. Saunders1, M. Rutter3, T. Graham2, A. Hart1
1St. Mark’s Hospital, London, United Kingdom, 2Barts Cancer Institute, Tumour Biology, London, United Kingdom, 3University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom
OP013
Evolution of corticosteroid use in Crohn’s disease patients between 1991 and 2014: results from the Dutch population-based Inflammatory Bowel Disease South Limburg cohort
S. Jeuring*1, 2, V. Biemans1, L. Liu1, T. Van den Heuvel1, 2, M. Zeegers3, 4, W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2
1Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, 4Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, 5Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, 6Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands
OP014
A multicentre, double-blind, placebo-controlled phase 3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn’s disease refractory to anti-tumour necrosis factor α: UNITI-1
P. Rutgeerts*1, C. Gasink2, M. Blank3, Y. Lang2, J. Johanns2, L.-L. Gao2, B. Sands4, S. Hanauer5, B. Feagan6, S. Targan7, S. Ghosh8, W. de Villiers9, J.-F. Colombel10, S. Lee11, P. Desreumaux12, E. V. Loftus, Jr13, S. Vermeire14, W. J. Sandborn15
1University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, 2Janssen R & D, LLC, Spring House, United States, 3Janssen Scientific Affairs, LLC., Horsham, United States, 4Mount Sinai Medical Centre, New York, New York, United States, 5Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 6Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, 7Cedars-Sinai Medical Centre, Division of Gastroenterology, Los Angeles, California, United States, 8University of Calgary, Department of Gastroenterology, Calgary, Canada, 9Universiteit Stellenbosch University, Stellenbosch, South Africa, 10Mount Sinai, Icahn School of Medicine, New York, New York, United States, 11University of Washington, Seattle, Washington, United States, 12University of Lille, Lille, France, 13Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States, 14University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, 15University of California San Diego, Division of Gastroenterology, La Jolla, California, United States
OP015
Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn’s disease who are anti-tumour necrosis factor inadequate responders
S. Danese*1, S. Vermeire2, P. Hellstern3, R. Panaccione4, G. Rogler5, G. Fraser6, A. Kohn7, P. Desreumaux8, R.W. Leong9, G.M. Comer10, F. Cataldi10, A. Banerjee10, M.K. Maguire11, C. Li10, N. Rath11, J. Beebe10, S. Schreiber12
1Humanitas University Clinical and Research Hospital, Rozzano, Milan, Italy, 2University Hospitals Leuven, Leuven, Belgium, 3Nature Coast Clinical Research, Inverness, Florida, United States, 4University of Calgary, Calgary, Canada, 5University of Zürich, Zürich, Switzerland, 6Rabin Medical Centre and University of Tel-Aviv, Petah Tikva, Israel, 7AO San Camillo Forlanini, Rome, Italy, 8University of Lille, Inserm U995, Lille, France, 9Concord Hospital, Sydney, New South Wales, Australia, 10Pfizer Inc, Cambridge, Massachusetts, United States, 11Pfizer Inc, Collegeville, Pennsylvania, United States, 12Christian-Albrechts University, Kiel, Germany
OP016
Development and validation of diagnostic criteria for IBD-unclassified (IBDU) in children: a multicentre longitudinal study from the paediatric IBD Porto Group of ESPGHAN
L. Birimberg Schwartz1, D. Zucker2, A. Akriv2, C. Salvatore3, F. Cameron4, I. Lazowska5, L. Yianni6, P. Siba7, S. Kolacek8, C. Romano9, S. Buderus10, A. Pærregaard11, J. C. Escher12, D. Turner*13
1Shaare Zedek Medical Centre, Paediatrics, Jerusalem, Israel, 2The Hebrew University, Jerusalem, Israel, 3Sapienza University of Rome, Rome, Italy, 4Yorkhill Children’s Hospital, Glasgow, United Kingdom, 5Medical University of Warsaw, Warsaw, Poland, 6University Hospital Southampton, Hampshire, United Kingdom, 7University of Dundee, Scotland, United Kingdom, 8Zagreb University Medical School, Zagreb, Croatia, 9University of Messina, Messina, Italy, 10St Marien Hospital, Bonn, Germany, 11Hvidovre University Hospital, Copenhagen, Denmark, 12Erasmus Medical Centre, Holland, Netherlands, 13Shaare Zedek Medical Centre, Jerusalem, Israel
OP017
Multi-donor intense faecal microbiota transplantation is an effective treatment for resistant ulcerative colitis: a randomised placebo-controlled trial
S. Paramsothy*1, M. Kamm2, 3, A. Walsh4, J. van den Bogaerde5, D. Samuel6, R. Leong6, S. Connor7, W. Ng7, R. Paramsothy7, N. Kaakoush8, H. Mitchell8, W. Xuan9, E. Lin10, T. Borody10
1University of New South Wales, St Vincent’s Clinical School, Sydney, Australia, 2St Vincent’s Hospital, Melbourne, Australia, 3Imperial College London, London, United Kingdom, 4St Vincent’s Hospital, Sydney, Australia, 5Nambour General Hospital, Nambour, Australia, 6Bankstown-Lidcombe Hospital, Sydney, Australia, 7Liverpool Hopsital, Sydney, Australia, 8University of New South Wales, School of Biotechnology & Biomolecular Sciences, Sydney, Australia, 9Ingham Institute, Sydney, Australia, 10Centre for Digestive Diseases, Sydney, Australia
OP018
The impact of ‘Crohn’s Disease-TReatment-with-EATing’ diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolism
V. Svolos*1, R. Hansen2, K. Hughes1, U. Z. Ijaz3, C. Quince4, D. Gaya5, R. Russell2, K. Gerasimidis1
1Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, 2Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, 3School of Engineering, University of Glasgow, Glasgow, United Kingdom, 4Warwick Medical School, University of Warwick, Warwick, United Kingdom, 5Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom
OP019
Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials
W. J. Sandborn1, B. E. Sands2, G. D’Haens*3, S. Vermeire4, S. Schreiber5, S. Danese6, J. Panés7, B. G. Feagan8, W. Reinisch9, W. Niezychowski10, G. Friedman10, N. Lawendy10, D. Yu10, D. Woodworth10, A. Mukherjee11, P. Healey11, H. Zhang10, C. Su10
1Division of Gastroenterology, University of California, San Diego, California, United States, 2Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States, 3Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, 4Dept of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, 5Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, 6IBD Centre, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, 7Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 8Robarts Research Institute, London, Ontario, Canada, 9McMaster University, Hamilton, Canada, 10Pfizer Inc, Collegeville, Pennsylvania, United States, 11Pfizer Inc, Groton, Connecticut, United States
OP020
Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: interim analysis from the Phase 2 FITZROY study
S. Vermeire*1, S. Schreiber2, R. Petryka3, T. Kuehbacher4, X. Hebuterne5, X. Roblin6, M. Klopocka7, E. Goldis8, M. Wisniewska-Jarosinska9, A. Baranovsky10, R. Sike11, C. Tasset12, A. Van der Aa12, P. Harrison12
1UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, 2University Medical Centre Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, 3Vivamed, Warsaw, Poland, 4Asklepios Hospital West Hamburg, Department of Internal Medicine, Gastroenterology, Hamburg, Germany, 5Archet 2 Hospital, Department of Gastroenterology, Nice, France, 6Saint Etienne Hospital, Department of Gastroenterology, Saint Priest en Jarez, France, 7University Hospital Nr. 2 im. Biziela, Department of Gastroenterology, Bydgoszcz, Poland, 8Policlinica Algomed, Department of Gastroenterology, Timisoara, Romania, 9Saint Family Hospital Medical Centre, Department of Gastroenterology and Endoscopy, Lodz, Poland, 10City Clinical Hospital #31, St Petersburg, Russian Federation, 11Szent Margit Hospital, Department of Internal Medicine and Gastroenterology III, Budapest, Hungary, 12Galapagos NV, Department of Development, Mechelen, Belgium
Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor, which has demonstrated high efficacy in patients with rheumatoid arthritis. This 20-week Phase 2 study was designed to evaluate the efficacy and safety of filgotinib in patients with active Crohn’s disease.